Premarket Gummy: PLTR at $26.30 right now will be a good daytrade long. Pretty sure its heading north today.
Van up earlier than stoney what the heck is going on.... Is PLTR your new horse vs CRSR.....? Nahhhhhh The Gummy of The Day You know. You bought some when I showed you dem pretty lights... YUP it's a Chinese EV company you have come to know and love the makes of the P7!!! XPeng secures RMB12.8B credit line to expand business operations Jan. 12, 2021 12:10 AM ETXPeng Inc. (XPEV) XPeng (NYSE:XPEV) has signed a strategic cooperation agreement with leading domestic banks, pursuant to which it will secure a credit line of RMB12.8B with an extensive range of credit facilities. The credit facilities are expected to support the Company’s business operations and expansion of manufacturing, sales and service capabilities, which will help optimize the efficiency of its cash management, cost control and other corporate functions. XPeng continues to show rapid growth in deliveries in Q4, +303% Y/Y with December's 5,700 units delivered representing a 326% growth rate Y/Y. XPEV's future delivery growth, investments in R&D, autonomous tech and European expansion could charge up future growth prospects... gummy of the day- XPEV
'Da capo! Nietzsche's greatest inspiration, he believed, was the idea that if one is in a state of perfect mental health one should be able to survey one's entire life and then, rising ecstatically to one's feet, shout 'Da capo! – Once more! Once more! Back to the beginning! Van I have heard you say exactly those words-- Nothing in investing is new. If that is the case "Flashbacks" are an method of realizing risk. You remember past schemes, past fake outs, past mistakes both for you and the market's interpretation of world events. And you aim to avoid making the same mistake twice. There is no looking forward in investing without also looking back.~si
I'm going to fall into my Oak Island lingo here... So far we have found a mysterious Chinese car and now we look back to yesterday... and we reflect on what worked well and we decide that YES there should be another even bigger day for Skillz.... and YES a stock can be a gymmy two days in a row!@ If it's a really really good stock. 2nd gummy of the day- SKLZ
Skillz initiated with a Buy at Stifel 06:41 SKLZ Stifel analyst Drew Crum initiated coverage of Skillz with a Buy rating and $28 price target. He believes Skillz is positioned to benefit from a favorable industry outlook for mobile gaming and should see significant growth and margin expansion over the next several years given its unique and differentiated model, Crum tells investors. --Curaleaf credit facility completed on favorable terms, says Roth Capital 10:51 CURLF Curaleaf completed a three-year, $50M credit facility this morning on favorable terms, Roth Capital analyst Scott Fortune tells investors in a research note. This, coupled with the recent pricing of a marketed offering for total gross proceeds of $215M, will be used to fund the company's "high-return" expansion projects in limited license markets, says the analyst. He continue to views the balance sheet favorably and expects to see leverage in the second half of 2021. Fortune reiterates a Buy rating on Curaleaf with a $14 price target. --GrowGeneration downgraded to Neutral from Buy at Ladenburg » --CuriosityStream initiated with a Buy at Benchmark 06:56 CURI Benchmark analyst Daniel Kurnos initiated coverage of CuriosityStream with a Buy rating and $22 price target. The pandemic has accelerated the shift to streaming and fact-based programming is likely to remain in high demand, while CuriosityStream has "barely begun to scratch the surface of advertising and program sales opportunities," all of which leave him seeing the company as well positioned to succeed, Kurnos tells investors. --Rapid7 price target raised to $102 from $80 at Mizuho » --908 Devices initiated with a Buy at Stifel 06:48 MASS Stifel analyst Daniel Arias initiated coverage of 908 Devices with a Buy rating and $65 price target. 908 Devices is "positioned squarely in the center" of two of the most attractive parts of the life sciences market, namely biologic drug development and applied science testing, argues Arias. The company's growth opportunity is significant today, and "even more significant as the company's platforms evolve," the analyst added. 908 Devices initiated with an Outperform at Cowen --T2 Biosystems: T2SARS-CoV-2 Panel can detect multiple variants of COVID-19 18:26 TTOO T2 Biosystems announced that its T2SARS-CoV-2 Panel, a molecular diagnostic test that detects SARS-CoV-2, the virus responsible for COVID-19 infections, is capable of detecting the multiple variants of the SARS-CoV-2 virus most recently identified in the United Kingdom, South Africa, and the United States. "As new strains of the COVID-19 virus emerge, it is critical that we ensure our technology continues to be an effective diagnostic solution during the ongoing pandemic," said T2 Biosystems' President and CEO, John Sperzel. "I'm proud that we can confidently say, after extensive analysis, that our T2SARS-CoV-2 Panel, which has demonstrated clinical sensitivity of 95 percent and specificity of 100 percent, can continue to help impact lives by detecting multiple variants of the SARS-CoV-2 virus." Clovis sees Q4 Rubraca global product revenues of $43M-$43.5M 15:31 CLVS Earlier, ahead of plans to discuss results with investors this week at the 39th Annual J.P. Morgan Healthcare Conference which is being held virtually January 10-14, Clovis Oncology announced its preliminary, unaudited global product revenues for the fourth quarter and full year ended December 31, reporting $43M-$43.5M in estimated Rubraca global product revenues for the fourth quarter of 2020, compared to $38.8M for Q3 2020 and $39.3M for Q4 2019. The company reported $164.2M-$164.7M in estimated Rubraca product revenues for FY 2020, compared to $143.0M for FY 2019. Clovis reports approximately $240M in cash and cash equivalents at December 31, 2020 which is expected to fund the company's operating plan into early 2023 based on current revenue and expense forecasts. "We are pleased with our strong finish to a challenging year, including achieving record quarterly and annual sales. We believe we have set the stage for an important year in 2021, as we seek to continue to grow Rubraca sales and advance our pipeline, including plans to report top-line ATHENA monotherapy data in the second half of the year, initiate a clinical development program for FAP-2286 in the first half of the year, and show initial efficacy data for the LIO-1 lucitanib and Opdivo combination trial at a medical meeting this year," said Patrick Mahaffy, President and CEO of Clovis Oncology.
Alright watch this move folks...... OH BOY BIG CONTROVERSY I JUST canceled my EV! No P7 for me............... SELLING XPEV!!!!!